Plain-English translation of NCT05981014 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Neoplasms research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new approach called autologous tumor-draining lymph node-derived lymphocytes (LNL) combined with chemotherapy for women with HER2-negative breast cancer. The treatment involves removing immune cells from your lymph nodes, growing more of them in a lab, and then putting them back into your body along with chemotherapy drugs. The goal is to help your immune system fight the cancer more effectively.
Some women with HER2-negative breast cancer don't respond well enough to standard chemotherapy alone, which means they have a lower chance of being cancer-free after surgery. This trial is exploring whether adding these immune cells might improve outcomes by boosting your body's natural ability to recognize and attack cancer cells.
You likely qualify if…
You likely don't qualify if…
You will first complete two rounds of standard chemotherapy. If your cancer shows stable disease, you'll undergo surgery to remove a tumor-draining lymph node, which doctors will use to grow immune cells in a lab over several weeks. You'll then receive a short course of preparatory chemotherapy followed by an infusion of your grown immune cells plus a medication to boost them. After this, you'll receive four more rounds of a different chemotherapy drug before having surgery to remove the breast cancer. The entire process takes several months and involves multiple hospital or clinic visits.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
China